Vivek Ramaswamy Net Worth 2024, (Forbes) Assets, Earnings

Vivek Ramaswamy is well known businessman and politician from the United States. Vivek Ramaswamy Net Worth is $950 Million as per 2024.From 2007 to 2014, Ramaswamy worked for the hedge firm QVT Financial.He co-managed the firm’s biotech portfolio as a partner.He was the chairman of OnCore Biopharma and Tekmira Pharmaceuticals when the two firms combined in March 2015.

He was also the chairman of the board of Arbutus Biopharma, a Canadian company.Ramaswamy remains Roivant’s sixth-largest stakeholder, with a 7.17% stake.Roivant has never made a profit.

Vivek Ramaswamy Net Worth 2024

Vivek Ramaswamy has an estimated Net Worth of $950 Million by Forbes as per 2024.His primary source of earning comes from his career as American businessman and politician.

Vivek Ramaswamy Assets and Earning

Ramaswamy has earned more than $260 million in salary, bonuses, and capital gains since launching Roivant.On paper, Ramaswamy’s 10% share in the company, which had a market valuation of $8.87 billion as of Thursday morning, is worth $887 million. Ramaswamy took Roivant public in 2021 via a combination with a blank-check firm valued at $7.3 billion.Strive Asset Manager, a “anti-woke” index fund he launched, was recently valued at $300 million.

Vivek Ramaswamy sold over $33 million in shares in his biotech company Roivant Sciences Ltd., while continuing to support his presidential campaign primarily with his own money.According to a regulatory statement filed Tuesday, the Republican presidential contender and entrepreneur sold 3 million shares for $11.05 each. He continues to own 51.9 million shares.

Vivek Ramaswamy Net Worth Growth

Vivek Ramaswamy Career and Achivements

Ramaswamy and Travis May co-founded Campus Venture Network, which published a private social networking website for university students who aspired to launch a business in 2017.The company was sold to the nonprofit Ewing Marion Kauffman Foundation in 2009.

Ramaswamy worked at the hedge fund QVT Financial from 2007 to 2014.He was a partner and co-managed the firm’s biotech portfolio.QVT’s biotech investments under Ramaswamy included stakes in Palatin Technologies, ConcertPharmaceuticals,Pharmasset,and Martin Shkreli’s Retrophin.

In a 2023 speech and in his book Woke Inc., Ramaswamy called Shkreli, whose company had greatly increased the cost of a life-saving drug, both “brilliant” and a pathological liar. He criticized the U.S. Department of Justice for prosecuting Shkreli, calling his fraud a victimless crime.

In 2014, Ramaswamy founded the biotechnology firm Roivant Sciences; the “Roi” in the company’s name refers to return on investment.The company was incorporated in Bermuda, a tax haven, and received almost $100 million in start-up capital from QVT and other investors, including RA Capital Management, Visium Asset Management, and the hedge fund managers D. E. Shaw & Co. and Falcon Edge Capital.

Ramaswamy appeared on the cover of Forbes in 2015, and said his company would “be the highest return on investment endeavor ever taken up in the pharmaceutical industry.”Before new clinical trials began, he engineered an initial public offering (IPO) in Axovant.Axovant became a “Wall Street darling” and raised $315 million in its IPO.

Roivant partnered with the private equity arm of the Chinese state-owned CITIC Group to form Sinovant.In 2017, Ramaswamy struck a deal with Masayoshi Son in which SoftBank invested $1.1 billion in Roivant.In 2019, Roivant sold its stake in five subsidiaries including Enzyvant, to Sumitomo Dainippon Pharma Ramaswamy made $175 million in capital gains from the sale.The deal also gave Sumitomo Dainippon a 10% stake in Roivant.

Ramaswamy has donated money to both Democrats and Republicans. In 2016, he contributed $2,700 to Dena Grayson’s campaign for Congress in Florida.He gave $30,000 to the Ohio Republican Party between 2020 and 2023.Ramaswamy considering running for the United States Senate in Ohio in 2022.

Read Also : Daniel Andrews Family Tree